Evgen Pharma PLC Poster Presentation of SFX-01 and Trial Update (2973J)

TIDMEVG

RNS Number : 2973J

Evgen Pharma PLC

04 December 2018

 
 For immediate release   4 December 2018 
 

Evgen Pharma plc

("Evgen" or "the Company")

Poster presentation of SFX-01 and clinical trial update

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that a trials-in-progress poster of the Company's Phase II trial of SFX-01 in metastatic breast cancer will be presented this week at the San Antonio Breast Cancer Symposium 2018 in San Antonio, Texas.

The poster, entitled STEM: SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer, will be presented in a poster session on Wednesday 5 December 2018. The poster gives the background to SFX-01 along with a description of the STEM trial including its primary and second endpoints.

After a positive interim readout, recruitment in the STEM trial concluded in July this year. The final patient on the trial will take her last dose of SFX-01 before the end of December 2018, meaning that the final readout of the trial is expected in February or March 2019.

The San Antonio Breast Cancer Symposium is on 4-8 December 2018 in San Antonio, Texas, at the Henry B. Gonzalez Convention Center. Further information is available at this link: www.sabcs.org.

A copy of the Evgen poster will be made available on the Company's website, www.evgen.com, following its presentation at the San Antonio symposium.

Enquiries:

 
 Evgen Pharma plc                            c/o [phone] 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Wills, Tilly Abraham        [phone] 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney (Corporate 
  Finance) 
  Rob Rees (Corporate Broking)                   [phone] 
 WG Partners LLP 
  Nigel Barnes, Claes Spång                 [phone] 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDFSLFWDFASEDE

(END) Dow Jones Newswires

December 04, 2018 02:00 ET (07:00 GMT)